GS-9857 in patients with chronic hepatitis C virus genotype 1–4 infection: a randomized, double-blind, dose-ranging phase 1 study

Journal of Viral Hepatitis

Volumn 23, Issue 8, 2016, Pages 614-622

  Rodriguez Torres, M ^a   Glass, S ^b   Hill, J ^c   Freilich, B ^d   Hassman, D ^e   Di Bisceglie, A M ^f   Taylor, J G ^g   Kirby, B J ^g   Dvory Sobol, H ^g   Yang, J C ^g   An, D ^g   Stamm, L M ^g   Brainard, D M ^g   Kim, S ^h   Krefetz, D ⁱ   Smith, W ^j   Marbury, T ^k   Lawitz, E ^l  

^a Department of Hematology and Oncology   (Puerto Rico)

^b PRA Health Sciences   (United States)

^c Avail Clinical Research   (United States)

^d North Kansas City School District   (United States)

^e Comprehensive Clinical Research ^*  (United States)

^f S LOUIS UNIV HLTH SCIENCES CENTER   (United States)

^g GILEAD SCIENCES   (United States)

^h WCCT Global Inc   (United States)

ⁱ PRA Health Sciences   (United States)

^j UNIVERSITY OF TENNESSEE MEDICAL CENTER   (United States)

^k ORLANDO CLINICAL RESEARCH CENTER   (United States)

^l UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

more..

Author keywords

GS 9857; hepatitis C virus; NS3 4A protease inhibitor

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ANTIVIRUS AGENT; ASPARTATE AMINOTRANSFERASE; GS 9857; PLACEBO; UNCLASSIFIED DRUG; VIRUS RNA;

ABNORMAL LABORATORY RESULT; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANTIVIRAL ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHRONIC HEPATITIS C; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG POTENCY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GENOTYPE; HEADACHE; HEPATITIS C VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT;

EID: 84978639831     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12527     Document Type: Article

References (17)

1. American Association for the Study of Liver Diseases/Infectious Diseases Society of America HCV Guidance Panel. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology 2015; 62: 932–954.
2. Lam BP, Jeffers T, Younoszai Z, Fazel Y, Younossi ZM. The changing landscape of hepatitis C virus therapy: focus on interferon-free treatment. Therap Adv Gastroenterol 2015; 8: 298–312.
3. Holmes JA, Thompson AJ. Interferon-free combination therapies for the treatment of hepatitis C: current insights. Hepat Med 2015; 7: 51–70.
4. Solbach P, Wedemeyer H. The new era of interferon-free treatment of chronic hepatitis C. Viszeralmedizin 2015; 31: 290–296.
5. Taylor J, Appleby T, Barauskas O et al. P0899: preclinical profile of the pan-genotypic HCV NS3/4A protease inhibitor GS-9857. J Hepatol 2015; 62: S681.
6. Kirby B, Yang J, Yang C et al. P0861: evaluation of the pan-genotypic HCV NS3/4A protease inhibitor GS-9857 in healthy volunteers. J Hepatol 2015; 62: S663.
7. ® (Telaprevir) Capsules, for Oral Use. Full prescribing information. Cambridge, MA: Vertex Pharmaceuticals Incorporated, 2013.
8. ® (Simeprevir) Capsules, for Oral Use. Full prescribing information. Titusville, NJ: Janssen Products, LP, 2015.
9. ® (Boceprevir) Capsules, for Oral Use. Full prescribing information. Whitehouse Station, NJ: Merck & Co. Inc., 2015.
10. ® (Ombitasvir, Paritaprevir, and Ritonavir Tablets; Dasabuvir Tablets), Co-Packaged for Oral Use. Full prescribing information. North Chicago, IL: AbbVie Inc., 2014.
11. Sarrazin C, Kieffer TL, Bartels D et al. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 2007; 132: 1767–1777.
12. Tong X, Chase R, Skelton A, Chen T, Wright-Minogue J, Malcolm BA. Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034. Antiviral Res 2006; 70: 28–38.
13. Reesink HW, Fanning GC, Farha KA et al. Rapid HCV-RNA decline with once daily TMC435: a phase I study in healthy volunteers and hepatitis C patients. Gastroenterology 2010; 138: 913–921.
14. Tong X, Bogen S, Chase R et al. Characterization of resistance mutations against HCV ketoamide protease inhibitors. Antiviral Res 2008; 77: 177–185.
15. Lenz O, Verbinnen T, Lin TI et al. In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435. Antimicrob Agents Chemother 2010; 54: 1878–1887.
16. Susser S, Welsch C, Wang Y et al. Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients. Hepatology 2009; 50: 1709–1718.
17. Palanisamy N, Danielsson A, Kokkula C et al. Implications of baseline polymorphisms for potential resistance to NS3 protease inhibitors in Hepatitis C virus genotypes 1a, 2b and 3a. Antiviral Res 2013; 99: 12–17.